DNA methyltransferase Inhibitors
3 drugsAbout DNA methyltransferase
DNA methyltransferases (DNMTs) are a family of enzymes that catalyze DNA methylation, an epigenetic modification that alters gene expression. This process plays a crucial role in regulating gene expression without changing the underlying DNA sequence.
DNMTs are compelling targets for drug development, particularly in oncology, due to their involvement in gene regulation. Aberrant DNA methylation patterns are frequently observed in various cancers, contributing to tumor development and progression. There is currently no genetic evidence data available linking DNMTs to specific diseases.
DNMTs are targeted by two FDA-approved small molecule drugs, DECITABINE (NIVAGEN PHARMS INC) and INQOVI (TAIHO ONCOLOGY), both used in oncology. These drugs modulate epigenetic mechanisms to combat disease.
Top DNA methyltransferase Drugs
The competitive landscape includes two companies with approved drugs: NIVAGEN PHARMS INC and TAIHO ONCOLOGY.
Limited competition suggests opportunity for new entrants, but also highlights potential market challenges.
DNA methyltransferase Drug Modality Landscape
Modalities
Routes of Administration
DNA methyltransferase is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like PROTACs or epigenetic editors could provide differentiation.
DNA methyltransferase Clinical Trials 812 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on DNA methyltransferase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 403 | 135 | 113 | 146 | 54% |
| Phase 2 | 330 | 103 | 60 | 165 | 63% |
| Phase 3 | 71 | 23 | 14 | 34 | 62% |
| Phase 4 | 8 | 2 | 1 | 5 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved DNA methyltransferase drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting DNA methyltransferase. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
DNA methyltransferase Drug Approval Timeline (2020 - 2020)
The first drug targeting DNMTs was approved in 2013 (DECITABINE), with the most recent approval in 2020 (INQOVI).
The approval timeline indicates a slow but steady interest in DNMT inhibition, suggesting potential for further development.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 312 (101 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on DNA methyltransferase. A trial counts if an approved drug acting on DNA methyltransferase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.